ALung Technologies raises $10.8 million
Artificial lung-like device developer ALung Technologies raised $10.8 million in a new round of debt financing according to an SEC filing posted this week. The money already raised in the round comes from 63 unnamed investors, according to the SEC filing. Pittsburgh-based ALung’s Hemolung device is an extracorporeal carbon dioxide removal system that works by removing carbon dioxide and delivering oxygen directly to a patient’s blood via a small catheter inserted into the jugular or femoral vein. The company said that the remaining $1.2 million it looks to raise includes notes that are to be issued to Equinox Securities Melvin Pirchesky as part of a commission, according to the filing. Early last month, ALung Technologies said its Hemolung RAS extracorporeal carbon dioxide removal device was selected for use in the world’s 1st pivotal trial of ECCO2R technology used to treat patients with acute respiratory failure. The U.K.’s National Institute for Health Research will supply $3.1 million (GBP £2.1 million) in funding for the 1,120 patient Rest trial, which looks to examine the effect of protective ventilation with veno-venous lung assist devices during respiratory failure. The trial will be jointly led by Queen’s University and Belfast Health and Social Services Trust, the company said. The post ALung Technologies raises $10.8 million appeared first on MassDevice.
Collaboration Combines CollPlants Proprietary rhCollagen-based BioInk Technology and United Therapeutics Regenerative Medicine and Organ Manufacturing Capabilities NESS ZIONA, Israel, November 12, 2018 -- (Healthcare Sales &Marketing Network) -- Col... Devices, Regenerative Medicine, Licensing CollPlant, United Therapeutics, Lung Biotechnology PBC, 3D bioprinting
ConclusionPatients who are at risk for SCA are patients who have had a cardiac arrest due to ventricular fibrillation (VF) or sustained ventricular tachycardia (SVT), those with familial or inherited condition with sudden cardiac arrest risk, myocardial infarction with an ejection fraction (EF) of less than or equal to 35%, dilated cardiomyopathy (including NICM), with an EF of less than or equal to 35%, ICD explanations, and other conditions with high risk of ventricular tachycardia (VT) or VF are candidates for the WCD.The sample of data was from 186 patients. However, more patients were likely candidates but may not hav...
ConclusionA diagnosis of LC following LTx remains rare. LC in the explanted lung seems to have no impact on survival for early ‐stage disease. LC in the transplanted or native remaining lung after LTx has poor prognosis.This article is protected by copyright. All rights reserved.
ConclusionPirfenidone and nintedanib do not modulate expression of senescence markers, levels of p ‐SMAD3 or the amount of fibrosis in IPF lungs. Treated patients have less histopathological evidence of acute lung injury at the time of lung transplantation.
This study aimed to evaluate preoperative nutritional assessment as a predictor of LTX outcomes.
CONCLUSION: In a post-LTx setting, LUS represents a clinical novelty as a feasible diagnostic and monitoring tool to identify pathological pulmonary complications in the early post-operative phase. PMID: 30414162 [PubMed - as supplied by publisher]
ConclusionPreoperative thoracic epidural placement provides improved analgesia without increased morbidity following lung transplantation.This article is protected by copyright. All rights reserved.
ConclusionPercutaneous lung nodule needle biopsy can be performed accurately using cone-beam CT with navigational overlay.
Artificial intelligence (AI) algorithms can yield impressive results when tested...Read more on AuntMinnie.comRelated Reading: AI can't replace radiologists for chest x-ray reads AI detects more malignant lung nodules on x-rays C-MIMI: AI automatically generates radiology impressions JAMA: 7 forces will drive adoption of AI in healthcare Is seeing believing in imaging artificial intelligence?